News | February 28, 2022
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
The entire integration and transition of the brands is expected to be completed by March 2022
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Dr. Muthu was last associated with Mankind Pharma
Subscribe To Our Newsletter & Stay Updated
